Loading…
Foghorn Therapeutics Inc. is projected to rise to $6.53 by 2027, a +10% move from its current price of $5.95. FHTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $5.68 | $5.94 | $6.22 | -0.09% |
| Jul 14 | $5.57 | $5.94 | $6.33 | -0.18% |
| Jul 15 | $5.49 | $5.93 | $6.42 | -0.28% |
| Jul 16 | $5.41 | $5.93 | $6.49 | -0.37% |
| Jul 17 | $5.35 | $5.92 | $6.55 | -0.46% |
| Jul 18 | $5.30 | $5.92 | $6.61 | -0.55% |
| Jul 19 | $5.24 | $5.91 | $6.66 | -0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.24 | $5.91 | $6.66 | -0.64% |
| Week 2 | $4.96 | $5.87 | $6.96 | -1.28% |
| Week 3 | $4.74 | $5.84 | $7.18 | -1.91% |
| Week 4 | $4.56 | $5.80 | $7.37 | -2.54% |
| Week 5 | $4.41 | $5.76 | $7.53 | -3.17% |
| Week 6 | $4.27 | $5.72 | $7.68 | -3.79% |
| Week 7 | $4.14 | $5.69 | $7.81 | -4.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Incorporated in 2015 and headquartered in Watertown, Massachusetts, the company operates in the Healthcare sector. It has a collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics is listed as an asset in the Healthcare space, with activities centered on advancing targeted cancer therapies across multiple indications.
Foghorn Therapeutics Inc. (FHTX) currently trades at $6.00. The asset has a market capitalization of $352.28M and is ranked 3368 by market cap. The current price sits within a defined technical structure, and the 30-day forecast indicates upside potential over the coming years.
Long-run projections show meaningful upside, with 2030 averaging $11.31 and a maximum of $19.10 (ROI 88.4%), and even higher levels by 2040 ($22.15 avg, ROI 269.1%) and 2050 ($37.89 avg, ROI 531.5%). Market participants should note the current technical context, including a neutral near-term sentiment and a high RSI, alongside notable upside in the year-by-year forecast.
A major floor 54.5% below — a decisive break under it would weaken the trend.
The nearest floor, 39.0% below — buyers have tended to step in here.
The nearest ceiling, 3.7% above — a clean break opens room to run.
A major ceiling 30.9% above — clearing it would confirm fresh momentum.
Key FHTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FHTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.84 | Buy | $5.80 | Buy |
| MA 10 | $5.35 | Buy | $5.43 | Buy |
| MA 20 | $4.72 | Buy | $4.98 | Buy |
| MA 50 | $4.38 | Buy | $4.66 | Buy |
| MA 100 | $4.79 | Buy | $4.72 | Buy |
| MA 200 | $4.85 | Buy | $4.85 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 72.64 | Sell |
| Stoch RSI (14) | 80.82 | Sell |
| CCI (20) | 121.61 | Buy |
| Williams %R (14) | -10.28 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 43.72 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 89.72 | Sell |
| TRIX (15) | 0.94 | Buy |
| Awesome (5,34) | 1.42 | Buy |
| Ultimate (7,14,28) | 76.23 | Sell |
| Momentum (10) | 1.92 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 6.32 | Sell |
| ADX (14) | 28.40 | Buy |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 80. The price trades above both the SMA50 ($4.33) and the SMA200 ($4.83). This places the stock in a posture where recent momentum has not translated into a decisive breakout beyond current resistance.
The 30-day range spans $4.34 to $8.29, with the current price of $6.00 sitting at the resistance level of $6.00 and above the support of $3.63. The asset exhibits volatility, with an annualized volatility of 90%. Overall, near-term dynamics show a balance between upside resistance and underlying strength from price levels above key moving averages.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.60 | $5.95 | $7.71 | 0% | Neutral | |
| $4.88 | $6.53 | $9.40 | +10% | Neutral | |
| $5.04 | $7.09 | $10.81 | +19% | Neutral | |
| $5.08 | $7.45 | $11.85 | +25% | Bullish | |
| $7.35 | $11.19 | $18.45 | +88% | Bullish | |
| $8.10 | $12.79 | $21.75 | +115% | Bullish | |
| $7.36 | $12.01 | $20.99 | +102% | Bullish | |
| $7.92 | $13.33 | $23.89 | +124% | Bullish | |
| $7.64 | $13.26 | $24.30 | +123% | Bullish | |
| $7.52 | $13.45 | $25.17 | +126% | Bullish | |
| $11.03 | $22.70 | $46.29 | +282% | Bullish | |
| $17.63 | $39.17 | $90.10 | +558% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.60 | $5.95 | $7.22 | +0.00% |
| August 2026 | $4.66 | $5.60 | $6.99 | -5.80% |
| September 2026 | $4.50 | $5.47 | $6.94 | -2.39% |
| October 2026 | $4.73 | $5.81 | $7.49 | +6.20% |
| November 2026 | $4.81 | $5.96 | $7.77 | +2.52% |
| December 2026 | $4.68 | $5.84 | $7.71 | -1.91% |
Click any year to see its month-by-month FHTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Foghorn Therapeutics Inc.'s 2026 outlook centres on $5.95, within a $3.60 to $7.71 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, FHTX could reach as high as $9.40, with a base case around $6.53 and support toward $4.88 — roughly +10% from $5.95. Price action looks broadly range-bound.
Expect FHTX to range from $5.04 to $10.81 through 2028. The $7.09 average target implies a +19% move from current prices. That is up +9% on the projected 2027 average. A consolidation phase looks the most probable path here.
The FHTX price prediction for 2029 points to an average of $7.45 (low $5.08, high $11.85) — a potential gain of +25% on today's $5.95. Momentum favours further upside here.
In 2030, FHTX is projected to trade between $7.35 and $18.45, averaging $11.19 — a potential gain of +88% from today's $5.95. That is up +50% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Foghorn Therapeutics Inc.'s 2031 outlook centres on $12.79, within a $8.10 to $21.75 range. That is up +14% on the projected 2030 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2032, FHTX could reach as high as $20.99, with a base case around $12.01 and support toward $7.36 — roughly +102% from $5.95. Buyers look set to stay in control over this stretch.
Expect FHTX to range from $7.92 to $23.89 through 2033. The $13.33 average target implies a +124% move from current prices. That is up +11% on the projected 2032 average. Momentum favours further upside here.
The FHTX price prediction for 2034 points to an average of $13.26 (low $7.64, high $24.30) — a potential gain of +123% on today's $5.95. Buyers look set to stay in control over this stretch.
In 2035, FHTX is projected to trade between $7.52 and $25.17, averaging $13.45 — a potential gain of +126% from today's $5.95. That is up +1% on the projected 2034 average. Momentum favours further upside here.
Foghorn Therapeutics Inc.'s 2040 outlook centres on $22.70, within a $11.03 to $46.29 range. That is up +69% on the projected 2035 average. That marks a +282% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, FHTX could reach as high as $90.10, with a base case around $39.17 and support toward $17.63 — roughly +558% from $5.95. Momentum favours further upside here.
Investing $1,000 in FHTX today (≈ 168.067227 FHTX) could be worth
$6,583.64
+$5,583.64 (+558%) by 2050 · US Dollar
Based on the average projected FHTX price of $39.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FHTXwould be worth at today's price.
$1,000 invested in FHTX on Jul 10, 2025 (≈ 185.185182 FHTX) would be worth
$1,101.85
+$101.85 (+10.2%) today · 1.10× · US Dollar
Based on a FHTX entry price of $5.4 vs. today's $5.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.3 | $1,122.64 | +12.3% |
| 1 month ago | $3.85 | $1,545.45 | +54.5% |
| 3 months ago | $4.59 | $1,296.3 | +29.6% |
| 6 months ago | $6.38 | $932.6 | -6.7% |
| 1 year ago | $5.4 | $1,101.85 | +10.2% |
| All time (5.0y) ago | $9.4 | $632.98 | -36.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FHTX forecast.
Our base-case forecast reaches $12.00 around 2031.
Implied market cap at $12.00: $704.57M
The multi-year forecast shows a bullish trajectory starting around 2029, with 2029’s average price of $7.30 and 2030’s average of $11.31, reaching a max of $19.10 and an ROI of 88.4%. In 2031 the average rises to $12.83 and continues higher through 2035 (2031: $12.83, 2032: $11.87, 2033: $13.32, 2034: $13.01, 2035: $13.04) with bullish sentiment continuing for each year. Looking further out, 2040 shows an average of $22.15 (max $46.76, min $10.05) with an ROI of 269.1, and 2050 projects an average of $37.89 (max $87.14, min $17.05) yielding an ROI of 531.5.
These figures illustrate substantial long-run upside under a bullish outlook, though they remain estimates and are not guaranteed. Investors should consider the uncertainty inherent in forward forecasts and the potential for deviations from the projections.
Tap a question to reveal the answer.
2030 forecast: min $7.22, avg $11.31, max $19.10; ROI 88.4%; sentiment BULLISH.
Long-run forecasts show bullish sentiment from 2029 onward, with 2030 avg $11.31 (max $19.10) and ROI 88.4%, plus 2040 avg $22.15 (ROI 269.1%) and 2050 avg $37.89 (ROI 531.5%). These are estimates, not guarantees.
The 2030 max is $19.10, which is below $20; however, 2031 max is $22.40 and 2040 max $46.76, offering potential above $20 in later years.
Current price is $6.00 and market capitalization is $352.28M.
Sentiment is NEUTRAL; RSI14 is 80. The stock trades above SMA50 ($4.33) and SMA200 ($4.83). The 30-day range is $4.34–$8.29, with support at $3.63 and resistance at $6.00.
Foghorn Therapeutics Inc. Community Discussion
0Share your Foghorn Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.